1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH; The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.
2. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458.
3. Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis 2016; 75: 196–202.
4. Luijten KM, Tekstra J, Bijlsma JW and Bijl M. The systemic lupus erythematosus responder index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012; 11: 326–329.
5. Furie R, Khamashta M, Merrill JT, et al.; for the CD1013 Study Investigators. Anifrolumab, an anti-interferon-a receptor monoclonal antibody, in moderate-tosevere systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376–386.
6. Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol 2021; 31: 20–29.
7. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369. Doi et al. 7
8. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554–561.
9. Franklyn K, Lau CS, Navarra SV, et al.; Asia-Pacific Lupus Collaboration. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621.
10. Morand EF and Mosca M. Treat to target, remission and low disease activity in SLE. Best Pract Res Clin Rheumatol 2017; 31: 342–350.
11. Petri M and Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol 2018; 70: 1790–1795.
12. Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005; 44: 1267–1276.
13. McElhone K, Castelino M, Abbott J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010; 37: 2273–2279.
14. Jolly M, Pickard AS, Block JA and Kumar RB. Diseasespecific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 2012; 42: 56–65.
15. Grootscholten C, Ligtenberg G, Derksen RH, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res 2003; 12: 635–644.
16. Inoue M, Shiozawa K, Yoshihara R, et al. The Japanese LupusPRO: a cross-cultural validation of an outcome measure for lupus. Lupus 2017; 26: 849–856.
17. Fukuhara S, Bito S, Green J, Hsiao A and Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998; 51: 1037–1044.
18. Fukuhara S, Ware JE Jr, Kosinski M, Kosinski M, Wada S and Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 1998; 51: 1045–1053.
19. Fukuhara S and Suzukamo Y. Manual of SF-36v2 Japanese Version. Kyoto: iHope International Inc., 2004.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
21. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.
22. Gladman DD, Ibanez D and Urowitz MB. Systemic ~ lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.
23. Petri M, Kim MY, Kalunian KC, et al.; OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550–2558.
24. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297–334.
25. Freire EA, Guimar~aes E, Maia I, et al. Systemic lupus erythematosus symptom checklist cross-cultural adaptation to Brazilian Portuguese language and reliability evaluation. Acta Rheumatol Port 2007; 32: 341–344.
26. Beaton DE, Bombardier C, Guillemin F and Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (1976) 2000; 25: 3186–3191.
27. Wallace DJ and Hann BH. Dubois’ lupus erythematosus and related syndromes. 9th ed. Edinburgh: Elsevier Inc, 2019, pp.598–605.
28. Liu T, Li G, Mu R, Ye H, Li W and Li Z. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients. Lupus 2014; 23: 958–963.